The WHO has declared the coronavirus outbreak a global pandemic in March 2020. Many studies are being carried out to find out the solution and treatment for this public health emergency. Research is being carried out for prognostic indexes such as impaired immunity and many biomarkers are coming into existence for early detection of COVID19 severity.
A preprint article mentions the COVID Severity Index(CSI) and how it is calculated.
The objective of this study was to develop a new simple hematological index prognostic index for COVID 19 severity state. With COVID Severity Index, we can prevent the severity of the disease and help in better prognosis and outcome of COVID patients. This observational cross-study was conducted on 250 patients of COVID 19. The mean age was 16 to 85 years of age. Males(148) were more than females(102). The majority of the COVID19 patients were in Stage 2 and Stage 3. The patients had undergone CBC test to check values of Hb, WBC, lymphocytes, monocytes. Based on this, a simple equation was followed taking into account three important parameters which are monocyte, lymphocyte count, lactate dehydrogenase which were good prognostic indicators for clinical outcome.
The CSI ((COVID Severity Index) index is calculated according to the following formula
Monocyte/Lymphocyte absolute count X by LDH (Lactate Dehydrogenase)/Upper normal reference laboratory range of LDH value. Any value of index below 0.60 was considered for mild cases, while 0.60 was considered for moderate cases and 1.55 was considered for severe cases. CSI (COVID Severity Index) is a new simple predictor of clinical outcome in patients with COVID 19 during the early stage of the disease. However, this study has some limitations as other parameters like CT scan results CRP and oxygen saturation are important but were not included.